

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT

OBTAINMENT OF THE DRUG CLINICAL TRIAL APPROVAL NOTICE FOR TIANGE DINGXUAN GRANULES

Recently, Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd. (四川光大製藥有限公司) (“**Sichuan Guangda**”), a subsidiary of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the “**Company**”), received the Drug Clinical Trial Approval Notice (Notice No.: 2026LP03296) approved and issued by the National Medical Products Administration of the People's Republic of China* (國家藥品監督管理局) (“**NMPA**”), approving the conduct of clinical trials of Tiange Dingxuan Granules (the “**Product**”) applied for by Sichuan Guangda for vestibular migraine (the syndrome of wind-phlegm with blood stasis disturbing the clear orifices). The relevant particulars are announced as follows:

KEY PARTICULARS OF THE DRUG CLINICAL TRIAL APPROVAL NOTICE

Generic Name: Tiange Dingxuan Granules

Dosage form: Granules

Specification: 7g per sachet (each 1g is equivalent to 2.97g of prepared Chinese medicinal herbs)

Registration Classification: Class 1.1 traditional Chinese medicine

Applicant: Sichuan Guangda Pharmaceutical Manufacturing Co., Ltd.

Approval conclusion: Upon examination in accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, the clinical trial application for Tiange Dingxuan Granules, which was accepted on 17 August 2026, complies with the relevant requirements for drug

registration. Subject to further refinement of the clinical trial protocol, approval is granted to conduct clinical trials of the Product for vestibular migraine (the syndrome of wind-phlegm with blood stasis disturbing the clear orifices).

DRUG DEVELOPMENT AND RELATED CONDITIONS

The formulation of the Product comprises *Gastrodia elata* (Tianma), *Pueraria lobata* (Gegen) and other Chinese medicinal ingredients. Its therapeutic functions are to dispel wind, resolve phlegm, promote blood circulation and relieve vertigo, and it is intended for vestibular migraine (the syndrome of wind-phlegm with blood stasis disturbing the clear orifices). Vestibular migraine is an episodic vestibular disorder associated with migraine, characterized primarily by recurrent spontaneous or induced vertigo and dizziness, often accompanied by symptoms such as migrainous headache, photophobia and phonophobia. Its diagnostic criteria were jointly proposed by the International Headache Society and the Bárány Society in 2012, and it was formally included in the International Classification of Headache Disorders, 3rd edition in 2018. According to the Chinese Guidelines for the Diagnosis and Treatment of Vestibular Migraine (2026), large-scale epidemiological data on this disease remain lacking in China. Estimates based on the annual migraine prevalence of 9.3% among people aged 18 to 65 in China indicate a sizeable patient population. According to publicly available drug labelling and regulatory approval information, no drug has yet been approved for the indication of vestibular migraine either globally or in China. Clinical treatment largely involves empirical use of medicines based on experience in acute and preventive migraine treatment, and there is a clear unmet clinical need.

In terms of non-clinical research, the Product has completed pharmacodynamic and toxicological studies under Good Laboratory Practice (GLP) conditions. Pharmacodynamic studies showed that the Product could improve pain sensitivity and impairments in balance and motor coordination in animal models of migraine, reduce plasma levels of nitric oxide and calcitonin gene-related peptide, and inhibit cortical spreading depolarization and c-fos protein expression in the vestibular nuclei. In toxicological studies, the maximum tolerated dose following a single administration in rats was approximately 293 to 327 times the clinical daily dose during the preventive treatment period, while the dose at which no obvious toxic reactions were observed following repeated administration for 13 weeks was 14.1 times the proposed clinical dose.

According to publicly available information, the Product is the first Class 1.1 innovative traditional Chinese medicine in China to enter clinical trials for registration purposes directly targeting the indication of vestibular migraine, and is a key product in the Company's innovative traditional Chinese medicine pipeline. The approval to conduct clinical trials of the Product marks phased progress in the Company's research and development in innovative traditional Chinese medicines and will help further enrich the Company's product pipeline and enhance the market competitiveness of its traditional Chinese medicine segment.

As at the date of this announcement, the cumulative direct investment expenses in research and development for Tiange Dingxuan Granules amount to approximately RMB7.3358 million.

This product was jointly developed by the Company and Dongfang Hospital, Beijing University of Chinese Medicine. The Company holds all rights to the product worldwide.

RISK WARNING

Under the relevant laws and regulations governing drug registration in China, after obtaining the Drug Clinical Trial Approval Notice, a drug must still undergo clinical trials and pass the review and approval of the NMPA before it can be manufactured and marketed. Given the particular nature of drug research and development, the process from clinical trials to production and marketing is lengthy, involves multiple stages and is susceptible to numerous unpredictable factors. There are therefore various uncertainties regarding the progress and results of clinical trials and the future market competition for the product. The Company will fulfil its information disclosure obligations in a timely manner in accordance with the progress of research and development. Investors are advised to pay attention to investment risks.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
27 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

** For identification purpose only*